ArticleApplied biochemistry and biotechnology2026
Neuroprotective Potential of Nardostachys jatamansi Extract via Keap1-Nrf2 Pathway Regulation in Parkinson's Disease.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The Kelch-like ECH-associated protein 1 (Keap1)-Nuclear factor E2-related factor 2 (Nrf2) pathway is integral to cellular defense mechanisms against oxidative and xenobiotic stress by neutralizing reactive oxygen species (ROS). An increase in ROS levels is a significant factor in the advancement of neurodegenerative diseases (NDDs). Consequently, the development of effective Keap1 inhibitors that disrupt the Keap1-Nrf2 interactions and subsequently enhance Nrf2's transcriptional activity may represent promising therapeutic avenues for NDDs. Given that Nardostachys jatamansi (N. jatamansi), a medicinal plant, has shown potential as a treatment for Parkinson's disease (PD), we sought to assess its influence on the Keap1-Nrf2 pathway. Our research demonstrates that the phytochemicals in the methanol extract of N. jatamansi can activate the Keap1-Nrf2-ARE signalling cascade. Computational analyses, including molecular docking and molecular dynamics simulations with AutoDock Vina and Desmond, respectively, revealed the binding properties of selected N. jatamansi compounds, of which 16 phytocompounds were confirmed in the methanol extract using LC/MS. In vitro assays demonstrated a dose-dependent interaction of the extract with both the BTB and β-propeller domains of Keap1, as well as inhibition of the BTB-Cullin3 interaction. The extract was assessed for its ability to protect N27 dopaminergic neurons from rotenone-induced neurotoxicity by activating the Nrf2-ARE pathway. It demonstrated dose-dependent ARE transactivation, suggesting Nrf2 dissociation from Keap1. Altogether, these observations indicate that phytocompounds derived from N. jatamansi offer significant potential for therapeutic or neuroprotective applications in Parkinson's disease.
Indexed as
Identifiers
42446772What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.